Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16928436 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2SLC22A6TDP1ALOX15MAPT | |
| SCHEMBL25375746 | 0.84 | MMP1 (0.40) | SMN1; SMN2TP53MMP1MMP2MMP3 | |
| SCHEMBL19359076 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6TDP1ALOX15MAPT | |
| SCHEMBL305577 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6TDP1ALOX15MAPT | |
| SCHEMBL5586418 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6TDP1MMP1MMP2 | |
| SCHEMBL31289248 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6TDP1ALOX15MAPT | |
| SCHEMBL9493358 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2SLC22A6ALOX15MAPT | |
| SCHEMBL19107014 | 0.81 | MMP1 (0.34) | SMN1; SMN2TP53MMP1MMP2MMP3 | |
| SCHEMBL19119699 | 0.81 | MMP1 (0.31) | SMN1; SMN2TP53MMP1MMP2MMP3 | |
| Glycolic Acid SCHEMBL4799296 | 0.80 | OR51E2 (0.43) | SMN1; SMN2TP53TET2KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4030921-B1 | WHEY-BASED NUTRITIONAL COMPOSITIONS FORTIFIED WITH CALCIUM | NESTLE SA (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-115960379-A | Preparation method and application of antibacterial polylysine film | 天津理工大学 | 2023-04-14 | — | — | CN | claimed |
| EP-2094097-B1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER NV (NL) | 2014-02-12 | — | — | EP | claimed |
| EP-2094097-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2009-09-02 | — | — | EP | claimed |
| US-20080268131-A1 | Edible aerated oil-and-water emulsion | CONOPCO INC, D/B/A UNILEVER | 2008-10-30 | — | — | US | claimed |
| WO-2008080738-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2008-07-10 | — | — | WO | claimed |
| US-6129925-A | Container filled with infusion liquids and infusion preparation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | claimed |
| US-12035861-B2 | Fibrous structures comprising particles and methods for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240173235-A1 | PERSONAL CARE COMPOSITIONS COMPRISING SILAHYDROCARBONS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117957018-A | Pharmaceutical composition and application thereof | 苏州亚盛药业有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11944696-B2 | Detergent product and method for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-11944693-B2 | Method for delivering an active agent | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20080268131-A1 | Edible aerated oil-and-water emulsion | CONOPCO INC, D/B/A UNILEVER | 2008-10-30 | — | — | US | disclosed |
| WO-2008080738-A1 | EDIBLE AERATED OIL-AND-WATER EMULSION | UNILEVER N.V. (NL) | 2008-07-10 | — | — | WO | disclosed |
| EP-1849008-A1 | SENSOR MOLECULES INCORPORATING A BORONIC ACID SENSOR GROUP | Cambridge Enterprise Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| EP-1699421-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | Chiron Corporation (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006079843-A1 | SENSOR MOLECULES INCORPORATING A BORONIC ACID SENSOR GROUP | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| WO-2005046589-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12035861-B2 | Fibrous structures comprising particles and methods for making same | FGB, CD68, SDCBP | SMN1; SMN2 1064/4885SLC22A6 3433/4885TDP1 998/4885 |
| US-11944696-B2 | Detergent product and method for making same | DAGLA, LIPA, DAGLB | SMN1; SMN2 1205/4885SLC22A6 4558/4885TDP1 1110/4885 |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | VCL, KRT18, TPM4 | SMN1; SMN2 566/4885SLC22A6 4701/4885TDP1 717/4885 |
| US-11944693-B2 | Method for delivering an active agent | ACTB, KRT18, ACTN1 | SMN1; SMN2 46/4885SLC22A6 2548/4885TDP1 1538/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | SMN1; SMN2 3637/4885SLC22A6 486/4885TDP1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.